RecruitingPhase I/IIEN original

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Chorowanie na nawracającego lub opornego chłoniaka z komórek B.
  • Posiadanie przynajmniej jednej widocznej zmiany nowotworowej.
  • Dobre funkcjonowanie narządów i szpiku kostnego.

✗ Disqualifies

  • Wcześniejsze leczenie terapią genetycznie zmodyfikowanych komórek T (w tym CAR-T).
  • Inne nowotwory w przeszłości (z pewnymi wyjątkami).
  • Przeszczepienie komórek macierzystych od obcego dawcy.
  • Przeszczepienie własnych komórek macierzystych w ciągu ostatnich 6 tygodni.
  • Niekontrolowane infekcje (grzybicze, bakteryjne, wirusowe).
  • Znana infekcja HIV, WZW B lub WZW C (chyba że wirus nie jest wykrywalny).
  • Podejrzenie lub potwierdzenie chłoniaka w mózgu lub rdzeniu kręgowym.
  • Problemy z sercem w ciągu ostatnich 6 miesięcy.

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
June 29, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (26)

Banner MD Anderson Cancer Center

Gilbert, United States

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, United States

Stanford Cancer Institute

Stanford, United States

Moffitt Cancer Center

Tampa, United States

Northside Hospital

Atlanta, United States

Midwestern Regional Medical Center, Inc.City of Hope Chicago

Park Ridge, United States

Norton Cancer Institute, St. Matthews Campus

Shelbyville, United States

University of MD, Greenebaum Comprehensive Cancer Center

Baltimore, United States

Hackensack University Medical Center

Hackensack, United States

Columbia University Irving Medical Center

New York, United States

University of Rochester Medical Center

Rochester, United States

The Ohio State University Wexner Medical Center - James Cancer Hospital

Columbus, United States

Tennessee Oncology, PLLC - Investigational Drug Services

Nashville, United States

Vanderbilt University

Nashville, United States

St. David's Medical Center

Austin, United States

The University of Texas, MD Anderson Cancer Center

Houston, United States

Virginia Oncology Associates

Norfolk, United States

Royal North Shore Hospital

St Leonards, Australia

Concord Repatriation General Hospital

Sydney, Australia

Royal Adelaide Hospital

Adelaide, Australia

Epworth Healthcare

East Melbourne, Australia

Jewish General Hospital

Montreal, Canada

McGill University Health Center

Montreal, Canada

Universitatsklinikum Wurzburg

Würzburg, Germany

Academisch Medisch Centrum

Amsterdam, Netherlands

King's College Hospital

London, United Kingdom

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.